Showing 4001-4010 of 9857 results for "".
- Pediatric Dermatology Incomes Up; Demand Persists: Surveyhttps://practicaldermatology.com/news/pediatric-dermatology-incomes-up-demand-persists-survey/2460735/Median total compensation for pediatric dermatologists has increased 37 percent since 2014, results of The Society for Pediatric Dermatology’s (SPD) latest compensation report show. The
- Launching from Nutrafol: New Pro-Strength Boostershttps://practicaldermatology.com/news/launching-from-nutrafol-new-pro-strength-boosters/2460713/New professional-strength boosters from Nutrafol extend the popular nutraceutical line, providing physicians the opportunity to individualize recommendations for each patient’s specific hair health needs. Hairbiotic MD is a professional-strength
- DermTech Adds to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-to-scientific-advisory-board/2460686/Drs. Lisa Beck and George Han are the newest members of DermTech’s Scientific Advisory Board, Lisa Beck, MD, is the co-director of the University of Rochester Medical Center for Allergic Disease Research a
- FDA Defers Approval of Revance's Toxin Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://practicaldermatology.com/news/fda-defers-approval-of-revances-toxin-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2460628/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r
- Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic Arthritishttps://practicaldermatology.com/news/bristol-myers-squibbs-deucravacitinib-performs-well-in-phase-2-study-in-patients-with-psoriatic-arthritis/2460605/Results from an ongoing Phase 2 study evaluating the safety and efficacy of Bristol Myers Squibb's deucravacitinib (BMS-986165) 6mg or 12mg once daily, compared with placebo in
- Safety and Tolerability Update for LEO's Tralokinumabhttps://practicaldermatology.com/news/safety-and-tolerability-update-for-leos-tralokinumab-1/2460590/LEO Pharma’s tralokinumab is well tolerated when used as monotherapy or in combination therapy with the topical corticosteroid (TCS) mometasone furoate, according to a late-breaking data analysis presented online at European Academy of Dermatology and Ve
- Vyne Therapeutics Announces Covered Status for Zilxi with Express Scriptshttps://practicaldermatology.com/news/yne-therapeutics-announces-covered-status-for-zilxi-with-express-scripts/2460557/Vyne Therapeutics Inc.’s Zilxi (minocycline) will be covered on Express Scripts' National Preferred, Flex, and Basic commercial formularies effective O
- Tattoos Impair Sweating, May Increase Risk of Heat-related Injuryhttps://practicaldermatology.com/news/tattoos-impair-sweating-may-increase-risk-of-heat-related-injury/2460539/New research finds that tattooed skin does not sweat as much as non-inked areas, which may have implications for the body’s ability to cool in people with extensive tattooing.
- Medimetriks Streamlines MM36 AD Development Programhttps://practicaldermatology.com/news/medimetriks-streamlines-mm36-ad-development-program/2460532/Medimetriks Pharmaceuticals, Inc. is moving forward with its MM36 (difamilast) Atopic Dermatitis Development Program following a meeting with the U.S. Food and Drug Administration (FDA). Medimetriks is now preparing to conduct a s
- Burt's Bees: Data Support Efficacy of Natural Skincarehttps://practicaldermatology.com/news/burts-bees-data-support-efficacy-of-natural-skincare/2460166/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc